

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/510876
				Filing Date	October 8, 2004
				First Named Inventor	Christine Power
				Art Unit	1614- 1647
				Examiner Name	Not Yet Assigned RM DEBERRY
Sheet	1	of	2	Attorney Docket Number	SLII-P01-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/RMD/	A1	4,588,585	5/13/86	Mark et al.	
	A2	4,737,462	4/12/88	Mark et al.	
	A3	4,879,111	11/7/89	Chong	
	A4	4,904,584	2/27/90	Shaw	
	A5	4,959,314	9/25/90	Mark et al.	
	A6	4,965,195	10/23/90	Namen et al.	
	A7	5,017,691	5/21/91	Lee et al.	
/RMD/	A8	5,116,943	5/26/92	Koths et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/RMD/	B1	WO 92/13095	8/6/92	Synergen, Inc.		
I	B2	WO 98/35043	8/13/98	Genetics Institute, Inc.		
	B3	WO 99/53942	10/28/99	Amgen, Inc.		
/RMD/	B4	WO 02/46225	6/13/02	Applied Research Systems ARS Holding		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/RMD/	C1	Abraham et al., "Expression and function of surface antigens on scleroderma fibroblasts," Arthritis Rheum, 34:1164-1172 (1991).			
	C2	Bucay et al., "Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," Genes & Development, 12:1260-1268 (1998).			
	C3	Granot et al., "Halofuginone: an inhibitor of collagen type I synthesis," Biochimica Biophys. Acta 1156:107-112 (1993).			
	C4	Hattori et al., "Bleomycin induced pulmonary fibrosis in fibrinogen null mice," J. Clin. Invest. 106:1341-1350 (2000).			
	C5	Heron et al., "Intracerebral Calcification in Systemic Sclerosis," Stroke, 30(10):2183-2185 (1999).			
	C6	Kostenuik et al., "Osteoprotegerin: A Physiological and Pharmacological Inhibitor of Bone Resorption," Curr. Pharm Des, 7(8):613-635 (2001).			
	C7	Leighton, "Drug Treatment of Scleroderma," Drugs 61(3):419-427 (2001).			
/RMD/	C8	Malyankar et al., "Osteoprotegerin is an $\alpha_v\beta_3$ -induced, NF- κ B-dependent Survival Factor for Endothelial Cells," Journal of Biological Chem., 275(28):20959-20962 (2000)			

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/510876
				Filing Date	October 8, 2004
				First Named Inventor	Christine Power
				Art Unit	1614 1647
				Examiner Name	Not Yet Assigned RM DEBERRY
Sheet	2	of	2	Attorney Docket Number	SLII-P01-001

/RMD/	C9	Martini et al., "Marked and Sustained Improvement Two Years After Autologous Stem Cell Transplantation in a Girl With Systemic Sclerosis," Arthritis Rheum. 42:807-811 (1999).	
	C10	Mathiesen et al., "The Clinical Significance of Slightly to Moderately Increased Liver Transaminase Values in Asymptomatic Patients," Scand J Gastroenterol., 34(1):85-91 (1999).	
	C11	McGaha et al., "Halofuginone, an Inhibitor of Type-1 Collagen Synthesis and Skin Sclerosis, Blocks Transforming Growth-Factor- β -Mediated Smad3 Activation in Fibroblasts," J. Invest Derm., 118:461-470 (2002).	
	C12	Min et al., "Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis," J. Exp. Med., 192:463-474 (2000).	
	C13	Morinaga et al., "Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor," Eur. J. Biochem., 254:685-691 (1998).	
	C14	Salant, et al., "Heymann nephritis: Mechanisms of renal injury," Kidney Int. 35:976-984 (1989).	
	C15	Shi-wen et al., "Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis," Arthritis Rheum, 40:1237-1244 (1997).	
	C16	Simonet et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell, 89:309-319 (1997).	
	C17	Smith et al., "Production and function of murine macrophage inflammatory protein-1 α in bleomycin-induced lung injury," J. Immunol., 153:4704-4712 (1994).	
	C18	Wigley et al., "Novel therapy in the treatment of scleroderma," Exp. Opin. Invest. Drugs, 10(1):31-48 (2001).	
	C19	Wigley et al., "The treatment of scleroderma," Curr. Opin. In Anti-inflam. & Immun. Invest. Drugs, 2:276-292 (2000).	
	C20	Yano et al., "Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor," J. Bone Miner Metab., 19:365-372 (2001).	
/RMD/	C21	Yasuda et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," Endocrinology, 139:1329-1337 (1998).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.